Nurix Therapeutics, Inc. Common stock NRIX
Analyst Ratings
- Consensus
- Buy — 14 Buy · 0 Hold · 0 Sell (14 analysts)
- Avg. Price Target
- $34.57 (+46.1% upside)
Key Stats
- Today's Range
- $21.40 – $24.01
- 50-Day Range
- $21.23 – $28.23
- 52-Week Range
- $8.20 – $28.23
- Volume
- 3.82 million shs
- Average Volume
- 1.75 million shs
- Market Cap
- $2.42 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 1.54%
- Days to Cover
- 2.43
About Nurix Therapeutics, Inc. Common stock
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Related Stocks
Compare head-to-head: NRIX vs LLY·NRIX vs JNJ·NRIX vs ABBV·NRIX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.